RTP Mobile Logo
Summer Oncology Nursing Series: Chronic Lymphocytic Leukemia — Session 1 (Webinar Audio Proceedings)
Released June 2021

Proceedings from the second in a series of 11 summer webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Ms Kristen E Battiato and Dr Jennifer Woyach. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with chronic lymphocytic leukemia.

    LEARNING OBJECTIVES

    • Apply available clinical information and research data to the therapeutic and supportive care of patients with chronic lymphocytic leukemia (CLL).
    • Appreciate the importance of clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status in the selection of systemic therapy for patients with newly diagnosed CLL.
    • Discuss the efficacy and safety of Bruton tyrosine kinase inhibition with acalabrutinib or ibrutinib for patients with CLL, and discern how this strategy can be optimally integrated into nonresearch treatment.
    • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how this regimen can be appropriately integrated into treatment decision-making.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with systemic therapies commonly used in the management of CLL, in order to support quality of life and continuation of therapy.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    Audio Program: This educational activity for 1.5 contact hours is provided by RTP during the period of June 2021 through June 2022.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1 contact hour is provided by RTP during the period of June 2021 through June 2022.

    This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSCLL2021/MTP1/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCLL2021/MTP1/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSCLL2021/MTP1/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCLL2021/MTP1/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSCLL2021/MTP1.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Kristen E Battiato, AGNP-C
    Advanced Practice Providers
    Memorial Sloan Kettering Cancer Center
    New York, New York

    No relevant conflicts of interest to disclose.

    Jennifer Woyach, MD
    Professor
    Division of Hematology
    Department of Internal Medicine
    The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio

    Advisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: June 2021
    Expiration date: June 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to program
(WIFI is recommended for best performance):